Cutaneous manifestations in patients with rheumatic diseases
Keywords:
rheumatic diseases; cutaneous manifestations; systemic lupus erythematosusAbstract
Introduction: Rheumatic diseases have highly heterogeneous manifestations and a wide range of systemic and cutaneous involvement.
Objective: To describe the cutaneous manifestations of patients with rheumatic diseases.
Method: A cross-sectional descriptive study was conducted at the Arnaldo Milián Castro Clinical and Surgical University Hospital from January 2022 to October 2024. Thirty-two patients diagnosed with rheumatic diseases and cutaneous manifestations seen in the Rheumatology Clinic in 2023 were studied. Data were collected through observation through dermatological examination and documentary analysis of outpatient clinical records.
Results: The female sex predominated (30, 93.8%), and the incidence was more frequent in those aged 50 years or older (14, 43.8%). The majority of patients (25, 78.1%) had systemic lupus erythematosus, with a female-to-male ratio of 11:1. Malar erythema was observed in 64.0% of this group, and non-scarring alopecia and cutaneous vasculitis (six each) and oral ulcers (three) were observed in those aged 25 to 29 years.
Conclusions: The majority of patients in the study had systemic lupus erythematosus, with a predominance of females, a gradual increase with age, urban origin, and malar erythema as a cutaneous manifestation.
Downloads
References
1. Temiz SA, Aslan S, Dursun R. Skin manifestations of rheumatological diseases. Reumatol Q [Internet]. 2023 [citado 03/09/2024]; 1(4): [aprox. 2p.]. Disponible en: https://qrheumatol.com/articles/skin-manifestations-of-rheumatological-diseases/
https://doi.org/10.4274/qrheumatol.galenos.2023.08370
2. Di Ludovico A, Rinaldi M, Lauriola F, Ciarelli F, La Bella S, Gualdi G, et al. The diagnostic role of skin manifestations in Rheumatic diseases in children: a creitical review of pediatric vasculitis. Int J Mol Sci [Internet]. 2024 [citado 18/10/2024]; 25(13): [aprox. 3p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/39000430/
https://doi.org/10.3390/ijms25137323
3. McGrath JA, Uitto J. Structure and Function of the Skin. En: Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D. Rook’s Textbook of Dermatology. 9th ed. [Internet]. United Kindom: Wiley Blackwell; 2016 [citado 18/10/2024]. Disponible en: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119709268
https://doi.org/10.1002/9781119709268
4. Sontheimer DE, Connolly MK, Fiorentino DF, Werth VP. Why rheumatologic skin disease. Ann Transl Med [Internet]. 2021 [citado 10/04/2023]; 9(5): [aprox. 2p.]. Disponible en: https://atm.amegroups.com/article/view/62514/html
5. Sociedad Española de Reumatología. El 4% de la población padece una enfermedad autoinmune sistémica y el 75% de afectados son mujeres [Internet]. España: Sociedad Española de Reumatología; 2024 [citado 18/10/2024]. Disponible en: https://www.ser.es/el-4-de-la-población-padece-una-enfermedad-autoinmune-sistemica-y-el-75-de-afectados-son-mujeres/
6. Aldeen SH, Alsaed O, Hammoudeh M, Lutf A, Razzakh PA, Ziyada A, et al. Epidemiology of musculoskeletal complaints annd diseases in Qatar: A cross-sectional study. Qatar Med J [Internet]. 2020 [citado 10/04/2023];(2):[aprox. 2p.]. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7684551/
https://doi.org/10.5339/qmj.2020.29
7. Tian J, Zhang D, Yao X, Xu Y, Yaqing H, Quianjin L. Global epidemiology of systemic lupus erythrmatosus: a comprehensive systemic analysis and modelling study. Ann Rheum Dis [Internet]. 2023 [citado 18/10/2024]; 82: [aprox. 2p.]. Disponible en: https://ard.bmj.com/content/82/3/351
8. Arenas-Guzmán R. Dermatología. Atlas, diagnóstico y tratamiento. Lupus eritematoso sistémico. 7ma ed. Ciudad de México: McGRAW-HILL; 2019, p. 172-177.
9. Arenas-Guzmán R. Dermatología. Atlas, diagnóstico y tratamiento. Esclerosis sistémica progresiva. 7ma ed. Ciudad de México: McGRAW-HILL; 2019, p. 194-199.
10. Connolly MK. Esclerosis sistémica (esclerodermia) y trastornos relacionados. En: Bolognia JL, Schaffer JV, Cerrroni L. Dermatología. 4ta ed. Elsevier: Amsterdan; 2018. Disponible en : https://shop.elsevier.com/books/dermatologia/bolognia/978-84-9113-365-0
11. Arenas-Guzmán R. Dermatología. Atlas, diagnóstico y tratamiento. Esclerosis sistémica progresiva. 7ma ed. Ciudad de México: McGRAW-HILL; 2019, p. 194.
12. Arenas-Guzmán R. Dermatología. Atlas, diagnóstico y tratamiento. Dermatomiositis. 7ma ed. Ciudad de México: McGRAW-HILL; 2019, p. 182.
13. Jorizzo JL. Dermatomiositis. En: Bolognia JL, Schaffer JV, Cerrroni L. Dermatología. 4ta ed. Amsterdan: Elsevier; 2018.
14. Lewis M, Fiorentino D. Dermatomyositis. En: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al. Fitzpatrick’s Dermatology. 9na ed. Ohio: Mc Graw Hill; 2019, p. 1061-1078.
15. Firestein GS. Etiología y patogenia de la artritis reumatoide. En: Firestein GS, Budd RC, Gabriel SE, Mcinnes IB, O’Dell JR. Tratado de Reumatología. 10ma ed. Amsterdan: Elsevier; 2017, p. 1115.
16. James WB, Elston DM, Treat JR, Rosembach MA, Neuhaus IM. Andrew’s Diseases of the skin. Clinical Dermatology. 20th ed. Amsterdan: Elsevier; 2020, p. 157-166.
17. Larrosa Padró M, Inoriza JM, Valls García R, Armengol Pérez E, Nolla JM, Coderch de Lassaletta J, et al. Prevalence of rheumatic diseases in Baix Empordá. Reumatol Clin (Engl Ed) [Internet]. 2022 [citado 10/04/2023]; 18(9): [aprox. 2p]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35523639/
https://doi.10.1016/j.reumae.2021.07.007
18. Sociedad Asturiana de Reumatología. Enfermedades reumáticas autoinmunes sistémicas [Internet]. España: Sociedad Asturiana de Reumatología; c2017 [citado 18/10/2024]. Disponible en: https://sare.org.es/enfermedades-reumaticas-autoinmunes-sistemicas/#:~:text=LUPUS%20ERITEMATOSO%20SIST%C3%89MICO%20(LES),Es%20la%ERAS%20m%C3%A1s%20frecuente
19. Goodfield M, Dutz J, McCourt C. Lupus Erythematosus. En: Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D. Rook’s Textbook of Dermatology. 9th ed. United Kindom: Wiley Blackwell; 2016, p. 51.1-51.39.
20. Bermúdez Garcell AJ, Serrano Gámez NB, Teruel Ginés R, Leyva Montero MD. Manifestaciones dermatológicas en pacientes con lupus eritematoso sistémico, estudio de 5 años. Rev Cubana med Milit [Internet]. 2023 [citado 03/09/2024]; 52(3): e02302561. Disponible en: https://revmedmilitar.sld.cu/index.php/mil/article/view/2561
21. Mucong L, Chaiquan L, Mengzhuo C, Ke L, Chanyuan W, Jinxi W, et al. Incidence and prevalence of systemic lupus erythematosus in urban China, 2013-2017: A nationwide population-based study. Sci Bull [Internet]. 2024 [citado 29/10/2024]; 69(19): [aprox. 2p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/39174401/
https://doi.10.1016/j.scib.2024.04.075
22. Tan Y, Yu F, Long J, Gan L, Wang H, Zhang L. Frequency of Systemic Lupus erythematosus was decreasing among hospitalized patients from 2013 to 2017 in a National database in China. Front Med [Internet]. 2021 [citado 10/04/2023]; 8:[aprox. 2p.]. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8056078/
https://doi.org/10.3389/fmed.2021.648727
23. Tang KT, Tsuang BJ, Ku KC, Chen YH, Lin CH, Chen DY. Relationship between exposure to air pollutans and development of systemic autoimmune rheumatic diseases: a nationwide population-based case-control study. Ann Rheum Dis [Internet]. 2019 [citado 10/04/2023]; 78(9): [aprox. 3p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30967397/
https://doi.org/10.1136/annrheumdis-2019-215230
24. Du F, Qian W, Zhang X, Zhang L, Shang J. Prevalence of oral mucosal lesions in patients with systemic lupus erythematosus: a systemic review and meta-analisis. BMC oral Health [Internet]. 2023 [citado 03/09/2024]; 23(1): [aprox. 2p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/38129844/
https://doi.org/10.1186/s12903-023-03783-5
25. Pons-Estel GJ, Saurit V, Alarcón GS, Hachuel L, Boggio G, Wojdyla D, et al. The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. Lupus [Internet]. 2012 [citado 03/09/2024]; 21(13): [aprox. 2p.]. Disponible en:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758687/
https://doi.org/10.1177/0961203312458465
26. Koichiro O. Which is the best SLE activity index for clinical trials? Mod Rheumatol [Internet]. 2021 [citado 03/09/2024]; 31(1): [aprox. 3p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32475188/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 William Alejandro Bermúdez Marrero, Yordan Martín Pozo, Damarys Pérez Fleites, Witjal Manuel Bermúdez Marrero, Yanelis Vizcaino Luna, Amelia Betancourt Pérez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who have publications with this journal agree to the following terms:
- Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
- Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
- Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
Sept 1 2025
